Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment

Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment

Abstract: Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was...

Full description

Saved in:
Bibliographic Details
Main Authors: Danai Dima, Aimaz Afrough, Utkarsh Goel, Ariel F. Grajales-Cruz, Jack Khouri, Kelley Julian, Oren Pasvolsky, Rahul Banerjee, Beatrice Razzo, Christopher J. Ferreri, Mariola A. Vazquez-Martinez, James A. Davis, Aishwarya Sannareddy, Omar Castaneda, Shahzad Raza, Andrew J. Portuguese, Mahmoud R. Gaballa, Masooma S. Rana, Alex Lieberman-Cribbin, Shaun DeJarnette, Rebecca Gonzalez, Anna Chen, Megan M. Herr, Lekha Mikkilineni, Hitomi Hosoya, Evguenia Ouchveridze, Gurbakhash Kaur, Adriana Rossi, Leyla Shune, Faiz Anwer, Yi Lin, Shambavi Richard, Douglas W. Sborov, Rachid C. Baz, Alfred L. Garfall, Hans C. Lee, Larry D. Anderson, Jr., Andrew J. Cowan, Krina K. Patel, Peter M. Voorhees, Surbhi Sidana, Doris K. Hansen, Shebli Atrash, Sandra P. Susanibar-Adaniya
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925002113
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952925002113

Similar Items